Pharmacological composition includes a type II anti-CD20 antibody, cell cytotoxicity depends on enhanced antibodies and one or more chemotherapists; and a drug used to treat a cancer that represents CD20.

摘要

The components of the drug include a class II anti-CD20 antibody whose Cytotoxicology depends on the enhanced antibody (CCDA) and one or more chemotherapeutic agents; and drugs for the treatment of CD20 cancer.